SE9402027D0 - Energy substrates - Google Patents

Energy substrates

Info

Publication number
SE9402027D0
SE9402027D0 SE9402027A SE9402027A SE9402027D0 SE 9402027 D0 SE9402027 D0 SE 9402027D0 SE 9402027 A SE9402027 A SE 9402027A SE 9402027 A SE9402027 A SE 9402027A SE 9402027 D0 SE9402027 D0 SE 9402027D0
Authority
SE
Sweden
Prior art keywords
organs
energy substrates
preparations
interrupted
alpha
Prior art date
Application number
SE9402027A
Other languages
English (en)
Inventor
Rolf Ekroth
Jan Wernerman
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE9402027A priority Critical patent/SE9402027D0/sv
Publication of SE9402027D0 publication Critical patent/SE9402027D0/sv
Priority to PCT/SE1995/000698 priority patent/WO1995034301A1/en
Priority to AU27584/95A priority patent/AU2758495A/en
Priority to ZA954775A priority patent/ZA954775B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
SE9402027A 1994-06-10 1994-06-10 Energy substrates SE9402027D0 (sv)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE9402027A SE9402027D0 (sv) 1994-06-10 1994-06-10 Energy substrates
PCT/SE1995/000698 WO1995034301A1 (en) 1994-06-10 1995-06-09 Energy substrates
AU27584/95A AU2758495A (en) 1994-06-10 1995-06-09 Energy substrates
ZA954775A ZA954775B (en) 1994-06-10 1995-06-09 Energy substrates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9402027A SE9402027D0 (sv) 1994-06-10 1994-06-10 Energy substrates

Publications (1)

Publication Number Publication Date
SE9402027D0 true SE9402027D0 (sv) 1994-06-10

Family

ID=20394327

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9402027A SE9402027D0 (sv) 1994-06-10 1994-06-10 Energy substrates

Country Status (4)

Country Link
AU (1) AU2758495A (sv)
SE (1) SE9402027D0 (sv)
WO (1) WO1995034301A1 (sv)
ZA (1) ZA954775B (sv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859001A (en) 1996-01-11 1999-01-12 University Of Florida Research Foundation, Inc. Neuroprotective effects of polycyclic phenolic compounds
US5880098A (en) * 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
PL369552A1 (pl) * 2004-08-12 2006-02-20 Sgp & Sons Ab Preparat farmaceutyczny lub/i żywieniowy lub/i laboratoryjny wzmagający, wspomagający funkcjonowanie komórek nerwowych i układu nerwowego oraz zastosowanie preparatu farmaceutycznego lub/i żywieniowego w procesie ochrony funkcji układu nerwowego oraz zastosowanie preparatu do ochrony wzrostu stymulacji namnażania i zapobiegania apoptozie komórek nerwowych
WO2006127902A1 (en) * 2005-05-26 2006-11-30 Ben O'mar Arrington Preservation solution for organs and biological tissues
PL379512A1 (pl) * 2006-04-21 2007-10-29 Sgp & Sons Ab Nowe metody i ich zastosowanie
WO2009005464A1 (en) * 2007-07-02 2009-01-08 Entress Ab New use of known pharmacologically active chemical compounds
CN109417016B (zh) 2016-05-01 2022-06-03 加州大学董事会 用于治疗缺血-再灌注损伤的戊二酸化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE11736T1 (de) * 1980-12-23 1985-02-15 Dr. Franz Koehler Chemie Gmbh Protektive loesung fuer herz und niere und verfahren zu deren herstellung.
WO1988001861A1 (en) * 1986-09-17 1988-03-24 Baxter Travenol Laboratories, Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic, vascular, cardiovascular, and/or thrombotic diseases
SE8704217D0 (sv) * 1987-10-29 1987-10-29 Vinnars Erik Ab Aminosyrakomposition for parenteral neringstillforsel
US4988515A (en) * 1988-01-28 1991-01-29 The Regents Of The Univ. Of Calif. Cardioplegic solution
DE3943424A1 (de) * 1989-12-30 1991-07-04 Nephro Medica Pharma Infusions- und injektionsloesung zur intravenoesen verabreichung
SE9201584D0 (sv) * 1992-05-20 1992-05-20 Vinnars Erik Ab Use of alpha-ketoglutarate

Also Published As

Publication number Publication date
ZA954775B (en) 1996-02-08
WO1995034301A1 (en) 1995-12-21
AU2758495A (en) 1996-01-05

Similar Documents

Publication Publication Date Title
BG102162A (en) Substituted (sulpphinic acid, sulphonic acid, sulphonylamino or sulphinylamino)n-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylam ide compounds
FI972628A (sv) Nya sulfonamider
MD1507F2 (en) Inhibitors, pharmaceutical composition on base thereof and process for HIV protease inhibition
EP0528858A4 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
DE3587649T2 (de) Fluorchemische Biuretzusammensetzungen und damit behandelte fasrige Substrate.
ES2160408T3 (es) Trifluorfenil-triazolpirimidinas fungicidas.
NO983529D0 (no) Dihydrobenzofuran og relaterte forbindelser anvendelig som anti-inflammatoriske midler
DE3763404D1 (de) Abscheidung von quecksilber aus erdgas.
EP0178189A3 (en) Pyridazinone derivatives, their preparation and use
BG103558A (en) Sulphonic acid or sulphonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
ATE86635T1 (de) Reinigung von rekombinantem interleukin-1.
SE9402027D0 (sv) Energy substrates
ATE76660T1 (de) Enzyme fuer den abbau von lignin.
ATE19095T1 (de) Chirurgische bindemittelsysteme zum verkleben von koerpereigenem hartgewebe gewuenschtenfalls mit kunststoff und/oder metall.
ES2058479T3 (es) Compuestos peptidicos.
TR199802538T2 (xx) �ltihaplanmaya kar�� maddeler olarak yararl� dihidrobenzopiran ve ili�kili bile�ikler.
DK540586D0 (da) Cardiotonisk virksomme thiazoloner
DE3581979D1 (de) Elektronenstrahlbehandlung zum erhoehen des haftvermoegens von polyesterfilmen.
RU95109909A (ru) Способ ингибирования ретровирусной инфекции, ингибитор протеазы, кодирующая его нуклеиновая кислота и способ рекомбинантного продуцирования серинового ингибитора
FI870460A (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 5-substituerade oktahydroindolizinderivat och vid foerfarandet anvaendbara mellanprodukter.
ATE267209T1 (de) Reinigung von carboxaldehyd
FR2421894A1 (fr) Nouvelles 2,3-dihydro-4h-1-benzopyranne-4-one-o-carbamoyloximes utiles notamment comme inhibiteurs de secretion gastrique
MY105242A (en) Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles.
SU610830A1 (ru) Композиционный материал